BPC-157 (Body Protective Compound) for ALS
Also known as: Body Protective Compound-157, Pentadecapeptide BPC 157
BPC-157's neuroprotective and tissue repair properties make it a candidate for motor neuron support in ALS.
Mechanism of Action
In ALS context, BPC-157 upregulates VEGF-R2 and EGF-R, promoting vascular and neurotrophic support for motor neurons. It modulates the nitric oxide system, reducing excitotoxic damage, and activates JAK-2/STAT-3 signaling for neuronal survival.
General mechanism: Pentadecapeptide that upregulates growth factor receptors, modulates nitric oxide, and activates JAK-2/STAT-3 for tissue repair and neuroprotection.
Current Evidence
Preclinical evidence shows neuroprotective effects in various CNS injury models. No ALS-specific clinical trials. Mechanism suggests potential for motor neuron support. Widely used in regenerative medicine research.
Clinical Status: Preclinical for neurological applications. No FDA-approved clinical trials for ALS.
Safety Profile
Excellent preclinical safety. No significant toxicity reported. Limited human safety data from controlled trials.
Key Research Questions
- Can BPC-157 reach motor neurons at effective concentrations via systemic administration?
- What is the interaction between BPC-157 and riluzole/edaravone?
- Does BPC-157's angiogenic activity benefit ALS motor neuron vascular supply?
Frequently Asked Questions
Is BPC-157 safe for humans?
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice. It has an excellent safety profile in animal studies with no reported toxicity even at high doses. Human clinical trials are limited. It's used in research and by some clinicians for tissue repair, but is not FDA-approved for any indication.
BPC-157 dosage for neuroprotection
Research dosages in animal studies translate to approximately 200-800mcg/day in humans (subcutaneous or oral). Some practitioners use 250-500mcg twice daily. Oral BPC-157 (stable gastric pentadecapeptide) may be sufficient for gut-brain axis effects. No standardized human dosing exists.